Lesión renal aguda y anemia hemolítica autoinmune inducida por rifampicina, una complicación poco frecuente y potencialmente mortal

Andrés José  García-Montoya; Sebastián Barrera-Escobar

doi:10.17533/10.17533/udea.iatreia.145

Authors

Andrés José García-Montoya IPS universitaria Clínica León XIII, Medellín, Colombia.
Sebastián Barrera-Escobar IPS Universitaria Clínica León XIII, Medellín, Colombia. https://orcid.org/0000-0001-5476-8013

DOI:

https://doi.org/10.17533/10.17533/udea.iatreia.145

Keywords:

Acute Kidney Injury, Hemolysis, Rifampin

Abstract

Rifampicin is a widely used drug for the treatment of various infectious diseases with a broad spectrum of adverse reaction ranging from mild to life-threatening manifestations; hemolytic anemia is an adverse effect rarely reported in the literature, but it can have a potentially fatal outcome. Thus, we report a case of autoimmune hemolytic anemia associated with acute kidney injury in a young patient in the second phase of treatment for pulmonary tuberculosis.

|Abstract

= 796 veces | HTML (ESPAÑOL (ESPAÑA))

= 0 veces| | PDF (ESPAÑOL (ESPAÑA))

= 265 veces|

Downloads

Download data is not yet available.

Author Biographies

Andrés José García-Montoya, IPS universitaria Clínica León XIII, Medellín, Colombia.

Internist physician, IPS universitaria Clínica León XIII, Medellín, Colombia.

Sebastián Barrera-Escobar, IPS Universitaria Clínica León XIII, Medellín, Colombia.

General Physician of IPS Universitaria Clínica León XIII, Medellín, Colombia.

References

(1) Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, et al. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases. Am J Respir Crit Care Med. 2007 Feb 15;175(4):367–416. DOI 10.1164/rccm.200604-571ST.

(2) Chen CY, Chen HY, Chou CH, Huang CT, Lai CC, Hsueh PR. Pulmonary infection caused by nontuberculous mycobacteria in a medical center in Taiwan, 2005-2008. Diagn Microbiol Infect Dis. 2012 Jan;72(1):47-51. DOI 10.1016/j.diagmicrobio.2011.09.009.

(3) De Vriese AS, Robbrecht DL, Vanholder RC, Vogelaers DP, Lameire NH. Rifampicin-associated acute renal failure: pathophysiologic, immunologic, and clinical features. Am J Kidney Dis. 1998 Jan;31(1):108–15.

(4) Martinez E, Collazos J, Mayo J. Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine (Baltimore). 1999 Nov;78(6):361–9.

(5) Girling DJ, Hitze KL. Adverse reactions to rifampicin. Bull World Health Organ. 1979;57(1):45–9.

(6) Muthukumar T, Jayakumar M, Fernando EM, Muthusethupathi MA. Acute renal failure due to rifampicin: a study of 25 patients. Am J Kidney Dis. 2002 Oct;40(4):690–6.

(7) Costiniuk CT, McCarthy AE, Talreja H, Zimmerman D, Liu TT, Owen E, Angel JB. Acute renal failure and disseminated intravascular coagulation associated with rifampin in tuberculosis treatment. Int J Tuberc Lung Dis. 2011 Mar;15(3):421.

(8) Manika K, Tasiopoulou K, Vlogiaris L, Lada M, Papaemmanouil S, Zarogoulidis K, Kioumis

I. Rifampicin-associated acute renal failure and hemolysis: a rather uncommon but severe

complication. Ren Fail. 2013 Sep;35(8):1179-81. DOI 10.3109/0886022X.2013.815567.

(9) Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003 Feb 15;167(4):603-62. DOI 10.1164/rccm.167.4.603.

(10) Covic A, Goldsmith DJ, Segall L, Stoicescu C, Lungu S, Volovat C, et al. Rifampicin-induced acute renal failure: a series of 60 patients. Nephrol Dial Transplant. 1998 Apr;13(4):924–9.

(11) Rosati S, Cherubini C, Iacomi F, Giannakakis K, Vincenzi L, Ippolito G, et al. Acute rifampicin-associated interstitial tubulopathy in a patient with pulmonary tuberculosis:

a case report. J Med Case Rep. 2013 Apr;7:106.

(12) Dhaliwal G, Cornett PA, Tierney LM. Hemolytic Anemia. Am Fam Physician. 2004;69(11):557-74.

(13) Croft JR, Swisher SN, Gilliland BC, Bakemeier RF, Leddy JP, Weed RI. Coombs’-Test Positivity Induced by Drugs: Mechanisms of Immunologic Reactions and Red Cell Destruction. Ann Intern Med. 1968 Jan 1;68(1):176–87. DOI 10.7326/0003-4819-68-1-176.

(14) Habibi B, Bretagne Y. Les antigènes de groupes sanguins peuvent être les cibles des conflits immunoallergiques médicamenteux à affinité érythrocytaire [Blood group antigens may be the receptors for immunoallergic drug complexes reacting with erythrocytes]. C R Seances Acad Sci III. 1983;296(15):693-6.

(15) Duran-Suarez JR, Martin-Vega C, Argelagues E, Massuet L, Ribera A, Triginer J. Red cell I antigen as immune complex receptor in drug-induced hemolytic anemias. Vox Sang. 1981;41(5–6):313–5.

(16) Pereira A, Sanz C, Cervantes F, Castillo R. Immune hemolytic anemia and renal failure associated with rifampicin-dependent antibodies with anti-I specificity. Ann Hematol. 1991 Jul;63(1):56–8.

(17) Lakshminarayan S, Sahn SA, Hudson LD. Massive haemolysis caused by rifampicin. Br Med J. 1973 May;2(5861):282–3.

(18) Sykes CA, Shepherd J, McGoldrick C, Kennedy N, Raafat A. A case of rifampicin-induced haemolysis. Int J Tuberc Lung Dis. 2019 Feb;23(2):239–40.

(19) Ahrens N, Genth R, Salama A. Belated diagnosis in three patients with rifampicin-induced immune haemolytic anaemia. Br J Haematol. 2002 May;117(2):441–3.